Justin Annes

Justin P. Annes, MD, PhD, Assistant Professor, Department of Medicine, Division of Endocrinology, Gerontology and Metabolism, Stanford University School of Medicine

 

Research Description: Dr. Annes is a physician scientist who directs a diabetes-focused research effort at Stanford University. His interdisciplinary research program studies the molecular basis of β-cell failure with the intent of identifying and developing small molecule therapeutics. His primary contributions to the field have been in the identification of novel pathways and small molecules that enhance β-cell function (glucose-stimulated insulin secretion) and replication. Currently a major effort of the laboratory is to develop high-throughput screening platforms to identify novel therapeutic targets, perform small molecule screening for hit compound identification and to develop lead series through rational drug design and structure-activity relationship studies. Dr. Annes directs the Stanford DRC Enrichment Program, and runs Stanford’s monthly Diabetes Research in Progress Seminar series. Additionally he is co-leader of the Pancreas and Islet Research Affinity Group of the Stanford DRC.

 

Selected relevant publications (Stanford DRC Members in BOLD):

1. Hosseini-Nassab N, Samanta D, Abdolazimi Y, Annes JP, Zare RN. Electrically controlled release of

     insulin using polypyrrole nanoparticles. Nanoscale. 2016 [Epub ahead of print] PMID: 27929180

2.  Zhao Z, Abdolazimi Y Armstrong NA, Annes JP. A high-content in vitro pancreatic islet β-cell

     replication discovery platform. J Vis Exp. 2016 Jul 16;(113).           

3. Zhao Z, Low YS, Armstrong NA, Ryu JH, Sun SA, Arvanites AC, Hollister-Lock J, Shah NH, Weir GC and Annes JP. Repurposing cAMP-Modulating Medications to Promote beta-Cell Replication. Molecular endocrinology 28(10):1682-97.  PubMed PMID: 25083741. *Selected as “The Best of Basic Science” (2014) by the Endocrine Society.

4. Vaidya A, Underwood PC, Annes JP, Sun B, Williams GH, Forman JP, et al. The influence of sodium-

     and calcium-regulatory hormone interventions on adipocytokines in obesity and diabetes. Metabolism:

     clinical and experimental 2013;62(4):539-47.

5. Wei, K, Piecewicz SM, McGinnis LM, Taniguchi CM, Wiegand SJ, Anderson K, Chan CW, Mulligan

     KX, Kuo D, Yuan J, Vallon M, Morton LC, Lefai E, Simon MC, Maher JJ, Mithieux G, Rajas F, Annes

     JP, McGuinness OP, Thurston G, Garcia AJ, Kuo, CJ.  A liver Hif-2 alpha-Irs2 pathway sensitizes

     hepatic insulin signaling and is modulated by Vegf inhibition. Nature Medicine 2013;19(10):1331-7.

6. Chen CA, Carolan PC, Annes JP. In vivo screening for secreted proteins that modulate glucose handling

     identifies interleukin-6 family members as potent hypoglycemic agents. PloS ONE. 2012;7(9):e4460.

7. Annes JP, Ryu JH, Lam K, Carolan PJ, Utz K, Hollister-Lock J, Arvanites AC, Rubin LL, Weir G, Melton DA.  Adenosine kinase inhibition selectively promotes rodent and porcine islet β-cell replication. Proc. Natl, Acad Sci U.S.A. 2012 Mar 109(10):3915-20.